Cosibelimab Alternatives Compared
Cosibelimab | Cetuximab | Keytruda (pembrolizumab) |
|
---|
Cosibelimab | Cetuximab | Keytruda (pembrolizumab) |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Squamous Cell Carcinoma. Cosibelimab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Head and Neck Cancer, Squamous Cell Carcinoma, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer. Cetuximab may also be used for purposes not listed in this medication guide. View more |
Prescription only
Keytruda is an immunotherapy treatment used to treat many different cancers in adults and children such as melanoma, non-small cell lung cancer, malignant pleural mesothelioma, head and neck squamous... View more |
Related suggestions Squamous Cell Carcinoma
|
|||||||
More about Cosibelimab | More about Cetuximab | More about Keytruda (pembrolizumab) | ||||||||
Ratings & Reviews | ||||||||||
Be the first to share your experience with this drug. |
Cetuximab has an average rating of 7.1 out of 10 from a total of 10 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 10% reported a negative effect. |
Keytruda has an average rating of 5.0 out of 10 from a total of 260 ratings on Drugs.com. 41% of reviewers reported a positive effect, while 47% reported a negative effect. |
||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
View all Cetuximab side effects |
View all Keytruda side effects |
|||||||||
Drug Class | ||||||||||
Generic Availability | ||||||||||
N/A |
N/A |
N/A |
||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Keytruda prices |
||||||||
Dosage Forms | ||||||||||
N/A |
N/A |
|
||||||||
Brand Names | ||||||||||
Unloxcyt | Erbitux |
N/A |
||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
427.2 hours |
213 hours |
624 hours |
||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Summary unavailable. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 612 drugs are known to interact with Cosibelimab:
|
A total of 23 drugs are known to interact with Cetuximab:
|
A total of 603 drugs are known to interact with Keytruda:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
Disease Interactions | ||||||||||
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||
First Approval Date | ||||||||||
N/A |
N/A |
N/A |
||||||||
WADA Class View classifications | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient Resources | ||||||||||
Professional Resources | ||||||||||
Related Treatment Guide | ||||||||||
|
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.